Brent Logan, PhD

Brent R. Logan, PhD

Director & Professor

Locations

Biostatistics

Contact Information

Education

PhD, Northwestern University, Evanston, IL, 2001
MS, Northwestern University, Evanston, IL, 1998
BS, Vanderbilt University, Nashville, TN, 1996

Research Experience

Multiple Comparison Procedures

Research Interests

Dr. Brent Logan joined the Division of Biostatistics in the Summer of 2001. He has methodological research interests in multiple comparison procedures, clinical trial design, and survival analysis. Research in multiple testing includes methods for analyzing multiple endpoints in clinical trials, analysis of dose-response studies, and multiplicity adjustment in functional MRI studies. His interests in clinical trial design include randomized phase 2 clinical trials and biologic assignment trials in bone marrow transplant studies. Recent work in survival analysis has focused on inference for competing risks and multistate models using pseudo-value regression, analysis in the presence of crossing survival curves, and methods for the analysis of complex bone marrow transplant data. He is a biostatistician for the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) and the Center for International Blood and Marrow Transplant Research (CIBMTR), as well as a statistical consultant for the National Marrow Donor Program.

Curriculum Vitae

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.

(Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA.) J Clin Oncol. 2022 02 01;40(4):356-368 PMID: 34855460 PMCID: PMC8797487 SCOPUS ID: 2-s2.0-85123901255 12/03/2021
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

(Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM.) Transplant Cell Ther. 2021 11;27(11):885-907 PMID: 34461278 PMCID: PMC8556300 SCOPUS ID: 2-s2.0-85116810681 08/31/2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.

(Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C.) J Clin Oncol. 2021 10 20;39(30):3328-3339 PMID: 34106753 PMCID: PMC8791814 SCOPUS ID: 2-s2.0-85112086284 06/10/2021
Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?

(Wingard JR, Alexander BD, Baden LR, Chen M, Sugrue MW, Leather HL, Caliendo AM, Clancy CJ, Denning DW, Marty FM, Nguyen MH, Wheat LJ, Logan BR, Horowitz MM, Marr KA.) Open Forum Infect Dis. 2021 Oct;8(10):ofab441 PMID: 34631917 PMCID: PMC8496761 10/12/2021
Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation.

(Kim HT, Logan B, Weisdorf DJ.) Transplant Cell Ther. 2021 08;27(8):650-657 PMID: 34004355 PMCID: PMC8489461 SCOPUS ID: 2-s2.0-85111042219 05/19/2021
COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum.

(Wingard JR, Ahn KW, Dandoy C, Perales MA, Wood WA, Logan B, Riches M, Rizzo JD.) Transplant Cell Ther. 2021 07;27(7):533-539 PMID: 33895401 PMCID: PMC8061634 SCOPUS ID: 2-s2.0-85107113196 04/26/2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.

(Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J.) J Clin Oncol. 2021 06 20;39(18):1971-1982 PMID: 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 04/28/2021
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.

(Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, Goldstein SC, Horowitz MM, Lazarus H, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, Shaw BE, Wingard JR.) Transplant Cell Ther. 2021 06;27(6):507-516 PMID: 33865804 PMCID: PMC8217124 SCOPUS ID: 2-s2.0-85108052714 04/19/2021
Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations.

(Panch SR, Logan B, Sees JA, Bo-Subait S, Savani B, Shah NN, Hsu JW, Switzer G, Lazarus HM, Anderlini P, Hematti P, Confer D, Pulsipher MA, Shaw BE, Stroncek DF.) Transplant Cell Ther. 2021 06;27(6):503.e1-503.e8 PMID: 33823169 PMCID: PMC8217152 SCOPUS ID: 2-s2.0-85103924669 04/07/2021
Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning.

(Logan BR, Maiers MJ, Sparapani RA, Laud PW, Spellman SR, McCulloch RE, Shaw BE.) JCO Clin Cancer Inform. 2021 05;5:494-507 PMID: 33950708 PMCID: PMC8443829 SCOPUS ID: 2-s2.0-85105478562 05/06/2021
Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study.

(Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, Shaw BE, Pulsipher MA.) Transplant Cell Ther. 2021 04;27(4):352.e1-352.e5 PMID: 33836890 PMCID: PMC8036235 SCOPUS ID: 2-s2.0-85101149566 04/11/2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.

(Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS.) JCO Precis Oncol. 2021;5 PMID: 34036237 PMCID: PMC8140814 05/27/2021